Case Studies: Carnot - Deployer

Launching the first sublingual

immunotherapy sprays for respiratory

and urinary infections in Mexico

Introduction

Carnot, a Mexican pharmaceutical company with a robust presence in therapeutic innovation, sought to enhance its immunotherapy portfolio by identifying cutting-edge treatments to address respiratory and urinary tract infections. Trifermed was engaged to support the identification of strategic partners and facilitate the licensing and market introduction of novel immunotherapy solutions.

Through Trifermed’s structured approach to strategic partnerships and portfolio development, Carnot signed a commercial agreement with Inmunotek, a European pharmaceutical company specialized in immunology, for the introduction of the first sublingual immunotherapy sprays in Mexico.

Background

With increasing interest in non-invasive preventive therapies, Carnot aimed to lead innovation in immunotherapy delivery in Mexico. The collaboration focused on two products: Bactek® SL and Uromune® SL, sublingual sprays designed to prevent recurrent respiratory and urinary infections, respectively.

The primary objectives were:

  • Identifying innovative products with robust clinical validation.

  • Establishing a licensing and commercial partnership with a leading developer.

  • Ensuring a structured negotiation process leading to a mutually beneficial partnership.​

Trifermed facilitated this partnership by drawing on its expertise in asset scouting, partner alignment, and deal structuring.

Services Provided

  • Portfolio Strategy & Asset Identification

  • Market Intelligence & Asset Scouting

  • Partner Identification & Negotiation Support

Outcomes & Future Development

Thanks to Trifermed’s facilitation, Carnot introduced Bactek® SL and Uromune® SL to the Mexican market through a licensing partnership with Inmunotek. This collaboration enabled:

  • Portfolio Expansion: Launching innovative immunotherapy solutions in a new format.

  • Market Differentiation: First-to-market advantage in sublingual spray immunotherapies.

  • Strategic Positioning: Reinforcing Carnot’s leadership in advanced therapeutic innovation.

Link